Clinical Trial Update: Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether granulocyte-macrophage colony-stimulating factor (GM-CSF) can restore monocytic immune competence in patients with sev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• sargramostim (sargramostim)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Sepsis | Phase 2 | Status: COMPLETED